Open Outbreak

Ebola virus disease

Also known as: Ebola, ebolavirus, Zaire ebolavirus, Bundibugyo ebolavirus, Sudan ebolavirus

Ebola virus disease is a rare but very serious viral illness. Large outbreaks in people are known to be caused by three related viruses: Ebola virus, Sudan virus and Bundibugyo virus. It usually starts after the virus passes from an infected animal into a person, then spreads between people through direct contact with blood or other body fluids, or with contaminated items. People are not thought to spread Ebola before symptoms start. The incubation period is 2 to 21 days. Illness often begins suddenly with fever, weakness, muscle pain, headache and sore throat, then may progress to vomiting, diarrhoea, abdominal pain, organ problems and sometimes bleeding. WHO says the average case fatality rate is around 50%, with past outbreaks ranging from 25% to 90%. Early supportive care improves survival. Licensed vaccines and antibody treatments exist for Ebola virus disease caused by Ebola virus, but WHO says approved vaccines or treatments are not yet available for Sudan or Bundibugyo disease.

Key facts

TransmissionDirect contact with blood or body fluids of a sick or dead person, contaminated objects, and spillover from infected wild animals; not thought to spread before symptoms begin.
Incubation2 to 21 days.
Case fatalityAverage around 50%; past outbreaks have ranged from 25% to 90%, depending on outbreak and virus species.
Reproduction numberunknown
VaccineApproved vaccines are available for Ebola virus disease caused by Ebola virus (Ervebo; Zabdeno and Mvabea). WHO says there is no approved vaccine yet for Sudan or Bundibugyo disease.
TreatmentEarly intensive supportive care improves survival. For Ebola virus disease caused by Ebola virus, WHO recommends the monoclonal antibodies ansuvimab (mAb114) or REGN-EB3 (Inmazeb). No approved therapeutics are listed by WHO for Sudan or Bundibugyo disease.
ReservoirThought to be fruit bats of the Pteropodidae family.
Endemic regionsOutbreaks mainly occur in sub-Saharan Africa, especially Central and West Africa.

Transmission

Ebola virus disease usually begins with a spillover from infected wild animals into humans. WHO says the natural host is thought to be fruit bats, and people can be infected through close contact with blood, secretions, organs or other body fluids from infected animals found ill or dead. After that, spread between people happens through direct contact with blood or body fluids from someone who is sick, or with contaminated objects and surfaces such as bedding or needles. WHO also notes that burial practices involving direct contact with the body can spread infection. People are not thought to transmit Ebola before symptoms begin, but they can remain infectious while virus is present in the blood. A 2016 systematic review also found the strongest risks with direct contact with a patient, body fluids, and participation in funeral and burial activities.

Symptoms and severity

Symptoms usually start suddenly after an incubation period of 2 to 21 days. WHO lists early symptoms as fever, fatigue, feeling unwell, muscle pain, headache and sore throat. These can be followed by vomiting, diarrhoea, abdominal pain, rash, and signs that the kidneys or liver are not working well. Bleeding can happen, but WHO says it is less common than many people think and may appear later in the illness. The disease can also affect the brain, causing confusion, irritability or aggression. Ebola is often severe and can be fatal. WHO says the average case fatality rate is about 50%, while past outbreaks have ranged from 25% to 90%. A major review in Nature Reviews Disease Primers describes Ebola as a severe disease with fever, stomach and bowel symptoms, and multiple organ dysfunction.

Treatment and vaccines

Early care matters. WHO says early intensive supportive care, including rehydration and treatment of specific symptoms, improves survival. This means careful fluids, symptom relief, nutrition, and treatment of other infections when present. For Ebola virus disease caused by Ebola virus, WHO recommends two antibody treatments: ansuvimab (mAb114) and REGN-EB3 (Inmazeb). WHO also says two vaccines are approved for this form of disease: Ervebo, and the two-dose Zabdeno and Mvabea regimen. But this protection is species-specific. WHO states that there is no approved vaccine or treatment yet for other Ebola diseases such as Sudan virus disease or Bundibugyo virus disease, although candidate products are in development. That difference is important in 2026 because the current large outbreak in central Africa is due to Bundibugyo virus, not Ebola virus, so the licensed Ebola-virus products do not solve the whole problem.

Where it occurs

Ebola outbreaks have mainly been reported in sub-Saharan Africa. WHO’s fact sheet describes Ebola disease as a recurring threat in African countries and notes the first recognized outbreaks in 1976 in what are now South Sudan and the Democratic Republic of the Congo. The Open Outbreak archive for this pathogen shows repeated WHO notices from the Democratic Republic of the Congo, Uganda, Guinea, Liberia, Sierra Leone and other countries affected by travel-related spread. The archive also includes imported or isolated cases in countries outside the usual outbreak zone, including Italy, Spain, the United Kingdom and the United States during the 2014 to 2015 period. In the current 2026 situation, WHO reports sustained Bundibugyo virus transmission in the Democratic Republic of the Congo, with imported cases reported in Kenya and Nigeria. So the main burden remains in Central and East Africa, but international travel can move cases across borders.

Recent history

This site’s archive lists 44 past Ebola-related events, showing that Ebola is not a one-off disease but a recurring outbreak problem. The largest event in the archive is the 2013 to 2016 West Africa epidemic. More recent WHO notices include Uganda in 2022 for Sudan virus disease, Guinea in 2021, and continuing Democratic Republic of the Congo outbreaks. In 2026, WHO has published a series of updates on a very large Bundibugyo virus outbreak in the Democratic Republic of the Congo. On 2026-07-03, WHO reported 1460 confirmed cases and 452 deaths in the DRC, alongside cases in Uganda. By 2026-11-06, WHO reported 10,668 confirmed cases and 5,198 deaths in the DRC, with imported cases also reported in Kenya and Nigeria. WHO assessed the risk in the DRC as very high, and also highlighted risk for neighboring countries because of cross-border spread.

What to watch

The main warning signs are changes that make spread harder to contain. One is expansion into new provinces or countries, especially when WHO starts reporting imported cases, as happened in Kenya and Nigeria in 2026. Another is sustained human-to-human transmission in cities, health facilities or along busy travel routes. WHO’s recent reports also stress the problem of many deaths occurring in the community rather than in care, because that can mean missed chains of transmission. For Ebola more broadly, it also matters which virus species is involved. If outbreaks are caused by Sudan or Bundibugyo virus, WHO says there are no approved vaccines or treatments yet, so vaccine supply for Ebola-virus-specific products does not fully answer the need. Better evidence of treatment failure, weaker infection control, or shortages in trial products and supportive care would all be concerning. Any sign of wider geographic spread outside the usual affected region should be watched closely.

Related outbreaks

Updated